The US Court of Appeals for the Federal Circuit today dismissed Amgen’s appeal of a previous district court ruling that denied its motion to compel discovery from Hospira in a Biologics Price Competition and Innovation Act (BPCIA) litigation.
The US Court of Appeals for the Federal Circuit today dismissed Amgen’s appeal of a previous district court ruling that denied its motion to compel discovery from Hospira in a Biologics Price Competition and Innovation Act (BPCIA) litigation.
In appealing the decision, Amgen had argued that, unless it was provided discovery of Hospira’s manufacturing process for epoetin alfa (Epogen), its right to sue over the cell-culture patents it holds for the drug would be thwarted. It alternatively sought a writ of mandamus, which would compel discovery.
The court, however, said that it lacked jurisdiction over the district court’s order, and found that Amgen failed to satisfy the prerequisites necessary for such a writ, calling it “a drastic remedy reserved for the most ‘extraordinary causes,’” in which the party has no other means of relief, and has demonstrated that it has a legal right to the writ by “clear and indisputable” means.
The court took the position that, barring an injunction under federal law (which the Supreme Court’s ruling in Sandoz v Amgen rendered unavailable), Amgen could have sought relief under state law (though it did not), sued for patent infringement, or coerced information from Hospira by bringing suit on its cell-culture patents. Moreover, the decision indicated, the Supreme Court appears to have provided for the possibility of the sponsor’s filing suit upon an applicant’s failure to disclose information.
The court stated that “the denial of discovery in this case does not undermine the purpose of the BPCIA," and that the district court was correct in its decision to deny Amgen’s motion.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.